Evidence map›Paper›PMID 39828008›Full record

ReviewBrain, behavior, and immunity2025

Advancing precision psychiatry and targeted treatments: Insights from immunopsychiatry.

Andrew H Miller, Michael Berk, Gilles Bloch, Veronique Briquet-Laugier, Carinne Brouillon, Bruce N Cuthbert, Robert Dantzer, Michael C Davis, Livia J De Picker, Wayne C Drevets and 13 more

Abstract readReview
In one paragraph

Review in Brain, behavior, and immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Big data and psychiatry: advances, constraints and future directions.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Biomarkers of reproductive psychiatric disorders.The British journal of psychiatry : the journal of mental science · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Andrew H MillerDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: amill02@emory.edu.
Michael BerkInstitute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine and Barwon Health, Deakin University, Geelong, VIC 3220, Australia.
Gilles BlochNational Museum of Natural History of France, Paris, France.
Veronique Briquet-LaugierFondation FondaMental, Créteil, France.
Carinne BrouillonBMD Human Pharma C.H. Boehringer Sohn AG & Co, KG Binger Str. 173 55216, Ingelheim am Rhein, Germany.
Bruce N CuthbertNational Institute of Mental Health, Bethesda, MD, USA.
Robert DantzerDepartment of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael C DavisUsona Institute, Fitchburg, WI, USA.
Livia J De PickerCollaborative Antwerp Psychiatric Research Institute, University of Antwerp, Antwerp, Belgium.
Wayne C DrevetsJanssen Research & Development, LLC, of Johnson & Johnson, San Diego, CA, USA.
Harris A EyreNeuro-Policy Program, Center for Health and Biosciences, The Baker Institute for Public Policy, Rice University, Houston, TX, USA.
Laura M HackDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Neil A HarrisonDivision of Psychological Medicine and Clinical Neuroscience, Cardiff University, Cardiff, UK.
Andrew D KrystalDepartment of Psychiatry, University of California, San Franscisco Weill Institute for Neurosciences, San Francisco, CA, USA.
Giulia LombardoInstitute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, Maurice Wohl Clinical Neuroscience Institute, King's College London, UK.
Valeria MondelliInstitute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, Maurice Wohl Clinical Neuroscience Institute, King's College London, UK.
Carmine M ParianteInstitute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, UK.
Luigi PulvirentiNeuroscience School of Advanced Studies, London, UK.
Giacomo SalvadoreClinical Development, Alector, Bethesda, MD, USA.
Luca SforziniInstitute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, Maurice Wohl Clinical Neuroscience Institute, King's College London, UK.
Pawel SwiebodaNeuroCentury, Brussels, Belgium.
Madhukar H TrivediDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Marion LeboyerUniv Paris Est Créteil, INSERM U955, IMRB, Translational NeuroPsychiatry Laboratory, Fondation FondaMental, Créteil, France.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kathrin Milbury · 1985 to 2026
$290.8M
The Metabolic Basis of Cancer-Related FatigueR01CA193522 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DANTZER, ROBERT · 2015 to 2023
$3.8M
The Role of Inflammation in CNS Mechanisms of Anhedonia and Psychomotor Slowing in Depressed PWH as Determined using a Next Generation TNF AntagonistR01MH128872 · NIMH · EMORY UNIVERSITY · PI Jennifer C Felger, ANDREW H MILLER · 2021 to 2026
$3.1M
Mitokines as new targets for fatigue induced by mitochondrial stressR21NS130712 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DANTZER, ROBERT · 2022 to 2022
$446k
Using Human iPSC Models to Determine the Mechanism of Inflammation-Induced Disruption of Dopamine NeurotransmissionR21MH132012 · NIMH · EMORY UNIVERSITY · PI MILLER, ANDREW H, WEN, ZHEXING · 2022 to 2023
$430k
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA193522NIMH NIH HHS R01 MH128872NIMH NIH HHS R21 MH132012NINDS NIH HHS R21 NS130712Wellcome Trust
6 · The paper itself

Abstract

Despite tremendous advancements in neuroscience, there has been limited impact on patient care. Current psychiatric treatments are largely non-specific, and drug development is hindered by outdated, overinclusive diagnostic categories and a "one-size-fits-all" approach. Additionally, mechanisms underlying psychiatric illnesses and their treatments with conventional medications remain poorly understood. Precision psychiatry is a strategy that holds great promise for novel therapies targeting specific pathophysiologic mechanisms in selected patients, ultimately contributing to more effective, personalized treatments. Immunopsychiatry, which focuses on the immune system's role in psychiatric disorders, exemplifies the challenges and potential solutions for precision psychiatry. Despite understanding how inflammation contributes to psychiatric illness, results of clinical trials with anti-inflammatory drugs have been inconsistent and underwhelming. Shortcomings of these trials include a lack of focus on subgroups of patients with increased inflammation, the use of non-specific outcome variables (e.g., not specific to inflammation's impact on the brain and behavior), and failure to establish target engagement of the inflammatory response. To advance anti-inflammatory treatments, clinical trials should: 1) enrich for patients using predictive biomarkers; 2) use clinical outcome assessments that align with inflammation's effects on the brain; 3) consider novel diagnostic constructs linked to inflammation; and 4) verify target engagement. Moreover, greater attention should be paid to efforts to repurpose available anti-inflammatory drugs while awaiting development of novel treatments targeting more specific immune pathways. Taken together, a collaborative approach involving academia, industry, funding agencies, patients, payors, and policymakers is required to advance Immunopsychiatry and ultimately provide a roadmap for successful implementation of precision psychiatry.

Indexed as

Mental DisordersPrecision MedicinePsychiatryAnti-Inflammatory AgentsHumansInflammationAnti-Inflammatory AgentsAnti-inflammatory drugsBiomarkersClinical Outcome AssessmentsClinical TrialsDepressionDrug developmentImmunopsychiatryInflammationPersonalized MedicinePsychiatry

Identifiers

PMID39828008
PMCPMC11903147

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.